FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302026744> ?p ?o ?g. }

• W4302026744 abstract "Abstract Background The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not known. The aim of this study was to compare the persistence of anti-Spike antibodies following two-dose SARS-CoV-2 vaccination between IMID patients and healthy controls and to identify factors associated with antibody decline. Methods IMID patients on immunosuppressive medication enrolled in the prospective observational Nor-vaC study were included. Participants received two-dose SARS-CoV-2 vaccination. Serum collected at two time points following vaccination (first assessment within 6–48 days, second within 49–123 days) were analyzed for antibodies binding the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. Multivariable regression models estimated percent reduction in anti-RBD over 30 days and factors associated with reduction. Results A total of 1108 patients (403 rheumatoid arthritis, 195 psoriatic arthritis, 195 spondyloarthritis, 124 ulcerative colitis, 191 Crohn’s disease) and 134 controls provided blood samples within the defined intervals (median 19 days [IQR 15–24] and 97 days [87–105] after second vaccine dose). Antibody levels were lower in patients compared to controls at both time points, with median anti-RBD 2806 BAU/ml [IQR 1018–6068] in patients and 6187 BAU/ml [4105–7496] in controls ( p <0.001) at first assessment, and 608 BAU/ml [IQR 58–1053] in patients and 1520 BAU/ml [979–3766] in controls ( p <0.001) at second assessment. At second assessment, low anti-RBD antibody levels (defined as <200 BAU/ml) were found in 449 (41%) patients, and 6 (5%) controls ( p <0.001). The change was − 83% in patients and − 66% in controls ( p <0.001). Patients had a greater estimated 30 days percent reduction in anti-RBD levels compared to controls − 4.9 (95% CI − 7.4 to − 2.4), ( p <0.05). Among therapies, mono- or combination treatment with tumor necrosis factor inhibitors was associated with the greatest decline. Conclusions Within 4 months after vaccination, antibody levels declined considerably in both IMID patients and controls. Patients had lower initial antibody levels and a more pronounced decline compared to healthy controls and were therefore more likely to decline to low antibody levels. These results support that IMID patients need additional vaccine doses at an earlier stage than healthy individuals." @default.
• W4302026744 created "2022-10-06" @default.
• W4302026744 creator A5000542169 @default.
• W4302026744 creator A5008586750 @default.
• W4302026744 creator A5011957275 @default.
• W4302026744 creator A5014171233 @default.
• W4302026744 creator A5016702384 @default.
• W4302026744 creator A5018839831 @default.
• W4302026744 creator A5025438429 @default.
• W4302026744 creator A5029345620 @default.
• W4302026744 creator A5033823447 @default.
• W4302026744 creator A5035671675 @default.
• W4302026744 creator A5039187353 @default.
• W4302026744 creator A5046032682 @default.
• W4302026744 creator A5059000621 @default.
• W4302026744 creator A5064983192 @default.
• W4302026744 creator A5070289679 @default.
• W4302026744 creator A5072837330 @default.
• W4302026744 creator A5076820474 @default.
• W4302026744 creator A5077105911 @default.
• W4302026744 creator A5085955224 @default.
• W4302026744 date "2022-10-05" @default.
• W4302026744 modified "2023-10-13" @default.
• W4302026744 title "The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study" @default.
• W4302026744 cites W2120393706 @default.
• W4302026744 cites W2140073887 @default.
• W4302026744 cites W2230558734 @default.
• W4302026744 cites W2572897530 @default.
• W4302026744 cites W2976362764 @default.
• W4302026744 cites W3027539208 @default.
• W4302026744 cites W3093667122 @default.
• W4302026744 cites W3094105410 @default.
• W4302026744 cites W3108610942 @default.
• W4302026744 cites W3111255098 @default.
• W4302026744 cites W3116076159 @default.
• W4302026744 cites W3133972824 @default.
• W4302026744 cites W3138645734 @default.
• W4302026744 cites W3139490202 @default.
• W4302026744 cites W3142193311 @default.
• W4302026744 cites W3157488589 @default.
• W4302026744 cites W3158750369 @default.
• W4302026744 cites W3163785571 @default.
• W4302026744 cites W3164069651 @default.
• W4302026744 cites W3164513520 @default.
• W4302026744 cites W3170450599 @default.
• W4302026744 cites W3172305468 @default.
• W4302026744 cites W3180511106 @default.
• W4302026744 cites W3184172540 @default.
• W4302026744 cites W3185122688 @default.
• W4302026744 cites W3188556989 @default.
• W4302026744 cites W3194596737 @default.
• W4302026744 cites W3196356596 @default.
• W4302026744 cites W3197081215 @default.
• W4302026744 cites W3197409924 @default.
• W4302026744 cites W3198017567 @default.
• W4302026744 cites W3198831432 @default.
• W4302026744 cites W3202238098 @default.
• W4302026744 cites W3202826390 @default.
• W4302026744 cites W3204733780 @default.
• W4302026744 cites W3206370075 @default.
• W4302026744 cites W3208126540 @default.
• W4302026744 cites W3209833474 @default.
• W4302026744 cites W3213247474 @default.
• W4302026744 cites W3217661335 @default.
• W4302026744 cites W4205368748 @default.
• W4302026744 cites W4205483821 @default.
• W4302026744 cites W4221045013 @default.
• W4302026744 cites W4225368559 @default.
• W4302026744 cites W4225413377 @default.
• W4302026744 cites W4225470021 @default.
• W4302026744 cites W4225854071 @default.
• W4302026744 cites W4226239921 @default.
• W4302026744 cites W4226376477 @default.
• W4302026744 cites W4229450998 @default.
• W4302026744 cites W4231972505 @default.
• W4302026744 doi "https://doi.org/10.1186/s12916-022-02587-8" @default.
• W4302026744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36199139" @default.
• W4302026744 hasPublicationYear "2022" @default.
• W4302026744 type Work @default.
• W4302026744 citedByCount "6" @default.
• W4302026744 countsByYear W43020267442022 @default.
• W4302026744 countsByYear W43020267442023 @default.
• W4302026744 crossrefType "journal-article" @default.
• W4302026744 hasAuthorship W4302026744A5000542169 @default.
• W4302026744 hasAuthorship W4302026744A5008586750 @default.
• W4302026744 hasAuthorship W4302026744A5011957275 @default.
• W4302026744 hasAuthorship W4302026744A5014171233 @default.
• W4302026744 hasAuthorship W4302026744A5016702384 @default.
• W4302026744 hasAuthorship W4302026744A5018839831 @default.
• W4302026744 hasAuthorship W4302026744A5025438429 @default.
• W4302026744 hasAuthorship W4302026744A5029345620 @default.
• W4302026744 hasAuthorship W4302026744A5033823447 @default.
• W4302026744 hasAuthorship W4302026744A5035671675 @default.
• W4302026744 hasAuthorship W4302026744A5039187353 @default.
• W4302026744 hasAuthorship W4302026744A5046032682 @default.
• W4302026744 hasAuthorship W4302026744A5059000621 @default.
• W4302026744 hasAuthorship W4302026744A5064983192 @default.
• W4302026744 hasAuthorship W4302026744A5070289679 @default.
• W4302026744 hasAuthorship W4302026744A5072837330 @default.
• W4302026744 hasAuthorship W4302026744A5076820474 @default.

• next